Disease | Dose of resveratrol | Model | Findings | Publish year | Refs. |
---|---|---|---|---|---|
PTSD-induced anxiety | 10, 20 and 40Â mg/kg | In vivo | Alleviate L-HPA axis, corticotrophin-releasing factor levels, and glucocorticoid receptor in the hypothalamus, hippocampus, and amygdala, increased pCREB and BDNF | 2018 | [108] |
PTSD-induced anxiety | 40Â mg/kg | In vivo | Alleviate L-HPA axis, elevated protein kinase A, phosphorylated CREB protein, and BDNF | 2020 | [109] |
Anxiety | 200 and 400Â mg/kg | In vivo | Anxiolysis and anti-psychotic effects | 2017 | [119] |
Ovariectomy-induced anxiety | 20Â mg/kg | In vivo | Decreased anxiety-like behaviors, decreased activation of microglia in the hippocampal dentate gyrus, hippocampal levels of NLRP3, and NF-kB, inhibited cytokine production, increased Sirt1 concentrations | 2019 | [85] |
Diabetes-induced anxiety | 10Â mg/kg/day | In vivo | Increased Sirt1 and Sirt7 | 2016 | [118] |
Anxiety | 1 and 2Â mg/kg | In vivo | Anxiolytic function | 2013 | [120] |